System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Jurgen M J Piek is an expert in Gynecology at Catharina Ziekenhuis (Netherlands). As of October 2026, ScienceLeadR ranks Jurgen M J Piek in the top 1% of experts worldwide for Ovarian Neoplasms, Adnexal Diseases and Gonadal Disorders. Jurgen M J Piek has authored 134 publications, the most recent in 2026, and is an investigator in 9 clinical trials, 6 of them ongoing. SLR score: 595 (community average: 125). How the SLR is computed.

LeadR Profile

Jurgen M J Piek Catharina Ziekenhuis Netherlands
595 ScienceLeadR Reputation 595

Unlock

Register Login
Network Map

Gynecology

Subspecialties: Oncology - Obstetrics - Endocrinology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2003 - 2026
Source: PubMed

Catharina Ziekenhuis

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 134

Citations

Citations: 1 888 1st author: 13 Last author: 37 Unique author: 3

Main journals

Gynecol Oncol 12
Cancers (Basel) 10
Int J Gynecol Cancer 8
Acta Obstet Gynecol Scand 6
BJOG 5

Best Journals

J Clin Oncol 2
JAMA 2
Cancer Cell 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
International trends in concurrent hysterectomy at risk-reducing surgery in BRCA1/2 pathogenic variant carriers: a mixed-methods study.
PMID 42323120 — salpingectomy, hysterectomy, ovary, neoplasms, obstetrics, ovarian neoplasms, gynecology, genes, brca1, salpingo-oophorectomy, ovariectomy, endometrial neoplasms		Am J Obstet Gynecol20260
Loss to follow-up in patients diagnosed with or treated for low- and high-grade squamous intraepithelial lesions: A comparison of general practitioner- and gynecologist-led surveillance.
PMID 42480977 — lost to follow-up, general practitioners, patient compliance, neoplasms, obstetrics, squamous intraepithelial lesions, gynecology, wounds and injuries, gynecologists		Acta Obstet Gynecol Scand20260
Recommendations for the use of CanRisk for tubo-ovarian cancer risk estimation: a focus group and Research ANd Development-modified Delphi-based study.
PMID 42301251 — focus groups, ovary, neoplasms, ovarian neoplasms, health personnel, research		Eur J Cancer Prev20260
ESGO Statements on Opportunistic Salpingectomy for Prevention of Tubo-Ovarian Carcinoma-Reply.
PMID 42258223 — salpingectomy, ovary, ovarian neoplasms		JAMA Top journal20260
Impact of pre-segmented regions on CT-based evaluation of the Peritoneal Cancer Index: A reader study.
PMID 42224186 — feedback, neoplasms, peritoneal neoplasms		PLoS One20260

Clinical Studies 9

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

N/A 7
Phase 2/Phase 3 2

By status:

Recruiting 5
Active not recruiting 1
Enrolling by invitation 1
Not yet recruiting 1
Unknown 1

By type:

Interventional 5
Observational 4

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 2
multicentric5to9 2
multicentricup10 3

Main Topics

Ongoing Clinical Trials

6 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Primary chemoradiation versus neoadjuvant chemotherapy followed by surgery as treatment strategy for locally advanced vulvar carcinoma (VULCANize2)
2022-502685-25-00 — drug therapy, therapeutics, chemotherapy, carcinoma		Phase 2/Phase 3Not yet recruiting2024
OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study
NCT06611072 — cells, flow cytometry, monocytes, bone marrow, blood, chromatin immunoprecipitation sequencing, ovary, neoplasms, phenotype, stem cells, biopsy, immunotherapy, dna methylation, myeloid cells, ovarian neoplasms, immune system, immunity, therapeutics, punctures, tissues, immunosuppression therapy, spleen, ficoll, dna, myeloid progenitor cells, rna, surgeons, sternum, carcinoma, bone and bones		N/ARecruiting2025
CADx Radiomics to Distinguish the Origin of Ovarian Tumors
NCT05174377 — support vector machine, computers, ovary, neoplasms, algorithms, radiology, ovarian neoplasms, therapeutics		N/ARecruiting2021
Liquid Biopsies for Improving the Pre operative Diagnosis of Ovarian Cancer
NCT04971421 — cells, blood, circulating tumor dna, micrornas, ovary, neoplasms, biopsy, algorithms, ovarian neoplasms, diagnosis, blood platelets, dna, liquid biopsy, carcinoma, ovarian epithelial, carcinoma		N/ARecruiting2021
Stop Ovarian Cancer Young Effect of the Opportunistic Salpingectomy on Age of Menopause
NCT04757922 — sterilization, salpingectomy, ovary, neoplasms, ovarian neoplasms, ligation, menopause, fallopian tubes, female		N/AEnrolling by invitation2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS